Italia markets closed

BioInvent International AB (publ) (0H22.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a watchlist
2,0900-43,0850 (-95,37%)
Alla chiusura: 10:17AM BST

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com

Settore/i
Settore
Impiegati a tempo pieno84

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Martin Welschof Ph.D.Pres & CEO4,75MN/D1961
Mr. Stefan Ericsson M.B.A.Chief Financial OfficerN/DN/D1963
Ms. Marie Moores M.Sc., R.G.N.Chief Operating OfficerN/DN/DN/D
Mr. Kristoffer Rudenholm HanssonSr. VP of Technical OperationsN/DN/D1974
Mr. Björn FrendéusChief Scientific OfficerN/DN/D1973
Ms. Cecilia HofvanderSr. Director of Investor RelationsN/DN/D1967
Dr. Andres McAllisterChief Medical OfficerN/DN/D1956
Ms. Ingrid TeigeHead of Preclinical ResearchN/DN/DN/D
Ms. Sylvie RyckebuschChief Bus. OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di BioInvent International AB (publ) al 1 luglio 2022 è 5. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.